文献速递细胞病理与分子病理神经与头颈病理

ThyroSeq v3 所测恶性概率随 AUS 亚型而异

Probability of malignancy as determined by ThyroSeq v3 genomic classifier varies according to the subtype of atypia.
PubMed 文献 · Cancer Cytopathol · 2022-07-01

该研究纳入 541 例细胞学诊断为意义未明的不典型(AUS)的甲状腺细针穿刺标本,按细胞异型(FC-C)、结构异型(FC-A)、两者兼有(FC-CA)或 Hurthle 细胞为主(PHC)分亚型,比较 ThyroSeq v3 的分子衍生恶性风险(MDROM)与组织学恶性风险(ROM)。结果显示各亚型分子改变谱与恶性概率不同,FC-CA 的 MDROM 与 ROM 最高。

要点

  • AUS 各亚型 MDROM 分别为 FC-A 15.9%、FC-C 20.5%、FC-CA 33.8%、PHC 14.4%。
  • FC-CA 亚型 MDROM 与 ROM 最高,BRAF V600E 与甲状腺乳头状癌最常见。
  • NIFTP 在 FC-C 亚型中显著更常见,RAS 突变见于所有亚型。

核心结论

  • AUS 亚型与特定基因改变、MDROM 及 ROM 相关。
  • 了解 AUS 各亚型的恶性概率有助于更个体化管理。

研究设计与样本

  • 回顾性分析 541 例细胞学 AUS 且行 ThyroSeq v3 检测的甲状腺细针穿刺标本。
  • 按 FC-A 233 例、FC-C 104 例、FC-CA 116 例、PHC 88 例分亚型。
  • 计算各亚型 MDROM、ROM 及分子改变频率,p<.05 为显著。

主要发现

  • AUS 总体良性呼叫率 72%、阳性呼叫率 28%,各亚型间有差异。
  • MDROM:FC-A 15.9%、FC-C 20.5%、FC-CA 33.8%、PHC 14.4%。
  • 155 例(28%)有≥12 个月组织学随访,各亚型 MDROM 的 95%CI 与 ROM 重叠。
  • FC-CA 亚型 MDROM 与 ROM 最高,BRAF V600E 与甲状腺乳头状癌最常见。
  • NIFTP 在 FC-C 亚型显著更常见,RAS 突变见于所有亚型。

关键数值与推荐

  • AUS 亚型划分:FC-C、FC-A、FC-CA、PHC。
  • MDROM:FC-A 15.9%、FC-C 20.5%、FC-CA 33.8%、PHC 14.4%。
  • AUS 总体良性呼叫率 72%、阳性呼叫率 28%。
  • 统计学显著性阈值 p<.05。

临床怎么用

  • 对 AUS 病例可结合细胞学亚型解读 ThyroSeq v3 分子结果。
  • FC-CA 亚型恶性概率较高,FC-C 亚型需注意 NIFTP。

局限性

  • 仅 155 例(28%)有≥12 个月组织学随访。
  • 各亚型 MDROM 的 95%CI 与 ROM 重叠。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ThyroSeq assesses the probability of malignancy (POM) in thyroid fine-needle aspiration cytology specimens diagnosed as atypia of undetermined significance (AUS). The authors investigated whether defined AUS subcategories are associated with specific molecular alterations, the molecular-derived risk of malignancy (MDROM), and the risk of malignancy (ROM). METHODS: Fine-needle aspiration cytology reports of AUS and corresponding results from the ThyroSeq version 3 genomic classifier results were retrieved and subcategorized as follicular cells with either cytologic atypia (FC-C), architectural atypia (FC-A), both cytologic and architectural atypia (FC-CA), or a predominance of Hurthle cells (PHC). The MDROM, ROM, and frequency of molecular alterations by subcategory were computed and analyzed, and p < .05 was considered significant. RESULTS: The final analysis included 541 cases subdivided into 233 with FC-A, 104 with FC-C, 116 with FC-CA, and 88 with PHC. The benign call rate and positive call rate for the AUS category were 72% and 28%, respectively, which varied between AUS subcategories. The MDROM by subcategory was 15.9% FC-A, 20.5% FC-C, 33.8% FC-CA, and 14.4% PHC. Histologic follow-up was available for 155 (28%) AUS cases with a follow-up period ≥12 months. The 95% confidence intervals of the MDROMs overlapped with the ROMs. The highest MDROM and ROM were in the FC-CA subcategory. RAS mutations were present in all subcategories. BRAF V600E mutations and papillary thyroid carcinoma were most frequent in the FC-CA subcategory. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features was significantly more frequent in the FC-C subcategory. CONCLUSIONS: The current results demonstrated that AUS subcategories are associated with specific genetic alterations, the MDROM, and the ROM. Molecular results and an awareness of various cancer probabilities within AUS subcategories can allow for a more tailored management.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Gajzer DC, Tjendra Y, Kerr DA, et al. Probability of malignancy as determined by ThyroSeq v3 genomic classifier varies according to the subtype of atypia. Cancer Cytopathol. 2022. PMID: 35775861. doi:10.1002/cncy.22617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。